Arcutis Biotherapeutics
ARQT
143 hedge funds and large institutions have $797M invested in Arcutis Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 32 reducing their positions, and 20 closing their positions.
254% more call options, than puts
Call options by funds: $3.99M | Put options by funds: $1.13M
113% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 32
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
8.72% more ownership
Funds ownership: 108.46% → 117.18% (+8.7%)
1% more funds holding
Funds holding: 141 → 143 (+2)
18% less capital invested
Capital invested by funds: $974M → $797M (-$177M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$33.4M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$20M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$16.3M |
| 4 |
Holocene Advisors
New York
|
+$13.4M |
| 5 |
Jennison Associates
New York
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$20.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.3M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$10.1M |
| 4 |
Millennium Management
New York
|
-$9.83M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.62M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ECM
151
ExodusPoint Capital Management
New York
| – | -$977K | -65,995 | Closed |
|
152
Squarepoint
New York
| – | -$536K | -36,227 | Closed |
|
|
SSA
153
Schonfeld Strategic Advisors
New York
| – | -$416K | -28,100 | Closed |
|
154
Russell Investments Group
London,
United Kingdom
| – | -$236K | -15,972 | Closed |
|
|
QT
155
Quantbot Technologies
New York
| – | -$215K | -14,500 | Closed |
|
156
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$206K | -13,900 | Closed |
|
|
AC
157
AXQ Capital
Jersey City,
New Jersey
| – | -$203K | -13,739 | Closed |
|
|
XT
158
XTX Topco
George Town,
Cayman Islands
| – | -$181K | -12,222 | Closed |
|
|
DTL
159
Dynamic Technology Lab
Singapore
| – | -$156K | -10,521 | Closed |
|
160
ProShare Advisors
Bethesda,
Maryland
| – | -$154K | -10,379 | Closed |
|
161
Nomura Holdings
Tokyo,
Japan
| – | -$9K | -585 | Closed |
|
162
US Bancorp
Minneapolis,
Minnesota
| – | -$7.1K | -480 | Closed |
|
163
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$246 | +17 | New |
|
ARQT Hedge Fund Activity: Q1 2023 in Review
143 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2023, worth a combined $797M — down 18% from $974M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ARQT positions and 20 closed out — a net gain of 2 holders — while 68 added to existing stakes and 32 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $33.4M. The largest seller was Logos Global Management, exiting entirely with an estimated $20.7M sold.
- 143 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2023, up from 141 in Q4 2022.
- Funds reported $797M of Arcutis Biotherapeutics stock for Q1 2023, down 18% quarter-over-quarter.
- 22 funds opened new Arcutis Biotherapeutics positions in Q1 2023 and 20 closed out, a net change of +2 holders.
- The largest Arcutis Biotherapeutics buyer in Q1 2023 was Marshall Wace, an estimated $33.4M added.
- The largest Arcutis Biotherapeutics seller in Q1 2023 was Logos Global Management, an estimated $20.7M sold.
Based on aggregated 13F filings for Q1 2023.